Attached files
| file | filename |
|---|---|
| EX-10.25 - EX-10.25 - Kiromic Biopharma, Inc. | a2241635zex-10_25.htm |
| EX-10.24 - EX-10.24 - Kiromic Biopharma, Inc. | a2241635zex-10_24.htm |
| EX-10.21 - EX-10.21 - Kiromic Biopharma, Inc. | a2241635zex-10_21.htm |
| EX-10.20 - EX-10.20 - Kiromic Biopharma, Inc. | a2241635zex-10_20.htm |
| EX-10.19 - EX-10.19 - Kiromic Biopharma, Inc. | a2241635zex-10_19.htm |
| EX-10.3 - EX-10.3 - Kiromic Biopharma, Inc. | a2241635zex-10_3.htm |
| EX-3.5 - EX-3.5 - Kiromic Biopharma, Inc. | a2241635zex-3_5.htm |
| EX-3.4 - EX-3.4 - Kiromic Biopharma, Inc. | a2241635zex-3_4.htm |
| EX-3.3 - EX-3.3 - Kiromic Biopharma, Inc. | a2241635zex-3_3.htm |
| S-1/A - S-1/A - Kiromic Biopharma, Inc. | a2241635zs-1a.htm |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement (No. 333-238153) on Form S-1 of our report dated April 6, 2020, (June 25, 2020 as to the effects of the reverse stock split described in Notes 2 and 12) relating to the financial statements of Kiromic BioPharma, Inc. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte & Touche LLP
Houston, Texas
June 25, 2020